We have developed a replication-competent human immunodeficiency virus (HIV) carrying a selective marker that can be used in vivo. This recombinant virus (Z6 ⌬ nef gpt) was generated by replacing the 5Ј half of the HIV nef gene with the Escherichia coli guanine phosphoribosyl transferase gene (gpt). This new vector can express the gpt product on infection and works as a positive selective marker for mycophenolic acid (MPA) resistance, a potent immunosuppressive drug used in organ rejection therapy. Conversely, gpt expression also served as a negative selectable marker, since its intracellular expression induces host-cell susceptibility to 6-thioxantine (6-TX), a nucleotide analog that is toxic to the infected cell under these conditions. In this manner, we could suppress the recombinant virus replication through 6-TX selection in both transformed cells and primary human peripheral blood mononuclear cells (PBMCs), suggesting the vector's potential as a model for a new live-attenuated vaccine approach against HIV.
INTRODUCTION
Live-attenuated vaccines have been used successfully as powerful tools to combat infectious diseases since the 1700s. Improvements in a smallpox live-attenuated vaccine developed by Jenner in 1796 led to the eventual eradication of this disease in 1972. A live-attenuated vaccine for the human immunodeficiency virus has been proposed (Desrosiers, 1992) based on a nef-deleted HIV (Kestler et al., 1991) . This vaccine approach has been found to be safe and effective in adult rhesus monkeys (Daniel et al., 1992) inoculated with a nef-deleted simian immunodeficiency virus (SIV). However, some nef-deleted vaccine strains as well as multiple-deleted SIV have been found to cause disease in inoculated newborn macaques or even adult animals (Baba et al., 1995 (Baba et al., , 1999 . Additionally, in some adult macaques, the deleted gene can be restored in vivo and induce immunodeficiency (Stahl-Hennig et al., 1996) .
In the Sidney Blood Bank Cohort, a blood donor and eight transfusion recipients were infected before 1985 with a strain of HIV-1 with a deletion in the region in which the nef gene and the long terminal repeat overlap. The five surviving recipients remain asymptomatic 14 to 18 years after HIV-1 infection without any antiretroviral therapy; however, the donor began therapy only in February 1999 (Greenough et al., 1999; Learmont et al., 1999) . These facts highlight concerns about this approach and challenge the scientific community to develop a safer live-attenuated preventive vaccine.
Recently, researchers have developed new candidate live-attenuated vaccines for HIV by introducing a "suicide" gene into the HIV-1 genome (Chakrabarti et al., 1996; Smith et al., 1996) . In these models, ganciclovir (GCV)-sensitive HIV-1 recombinant viruses were constructed by replacing half of the nef reading frame with the herpes simplex virus type I (HSV-1) thymidine kinase (tk) gene. GCV treatment of cells infected with HIV-tk effectively prevented virus spread in human cell cultures and in hu-PBL-SCID mice. Following a similar approach, the main goal of this work was to develop a strategy that can be used in an alternative candidate live-attenuated vaccine for HIV carrying a new suicide gene. For that, we chose to replace the HIV nef gene with the xanthine guanine phosphoribosyl transferase (GPT) (Mulligan et al., 1980) , a bacterial analog of the mammalian enzyme hypoxanthine phosphoribosyl transferase (HPRT). This bacterial enzyme can be used as either a positive or negative selective marker and has reduced toxicity to mammalian cells. GPT has a high affinity for xanthine, whereas HPRT cannot metabolize this purine. It is therefore possible to select for gpt expression in HPRT-expressing cells (HPRT ϩ ) by inhibition of de novo purine synthesis with mycophenolic acid (MPA) and inclusion of xanthine as a purine substrate . It is also possible to select against gpt expression in HPRT ϩ primary cells by taking advantage of the differential sub-strate specificity of the two enzymes and using 6-thioxanthine (6-TX) as a counter-selective agent. Under these conditions, GPT will phosphorylate this nucleoside analog and the cell will metabolize it to 6-thioguanine, a powerful toxic purine that blocks cellular-DNA replication (Besnard et al., 1987) . Such recombinant virus could be used as a safer live-attenuated HIV-1 vaccine, since the vaccine strain could be abrogated with 6-TX treatment if, for any reason, the vaccinees develop AIDS symptoms.
Here, we document the construction of a recombinant HIV-1 that carries the E. coli gpt gene, replacing the viral nef gene. On infection, this virus induced the expression of the bacterial enzyme and transduced resistance to MPA. Lymphocytic cell lines carrying a proviral copy of this recombinant HIV-1 were 6-TX sensitive. Moreover, 6-TX can abrogate the replication of the recombinant virus in human PBMCs.
RESULTS

Biological characterization of Z6 ⌬ nef gpt
The manipulation of the 3Ј end of the genome did not interfere with the normal replicative cycle of HIV, as demonstrated by the viral kinetics posttransfection between Z6 and both constructs (Z6 ⌬ nef gpt and Z6 fsnef; see Fig. 1 ). The supernatant containing 10 4 TCID50 units from the transfection was used to infect PM-1 CD4 ϩ T-cells, permissive to both T-and M-tropic virus, with a m.o.i. of 0.1. The Z6 ⌬ nef gpt virus replicated rapidly and reached peak titers by 12 days postinfection, once again generating a viral replication curve similar to that of Z6 and its nef (Ϫ) counterpart (Z6 fsnef; data not shown). PM-1 cells infected with Z6 ⌬ nef gpt produced a 17.0-kDa protein specifically recognized by antibody against E. coli gpt peptide in an immunoprecipitation reaction (Fig. 2) . The recombinant enzyme could be detected from 4 to 25 days postinfection. A natural enzyme extracted from the cytosolic fraction of an E. coli strain harboring pMSG plasmid was included in the immunoprecipitation reaction and could also be recognized by the antiserum, showing the same migration in the SDS-PAGE (Fig. 2,  lane 2) .
The viral replication was also studied in human PBMCs, using 10 4 TCID50 of Z6, Z6 fsnef, or Z6 ⌬ nef gpt to infect 5 ϫ 10 5 activated PBMCs. The infection kinetics of these three viruses were similar (Fig. 3A) and the genetic stability of the Z6 ⌬ nef gpt virus was analyzed by PCR amplification of the 3Ј end of provirus generated after four serial passages in hu-PBMCs (Fig. 3B) . This virus proved to carry a genetically stable gpt gene insertion, with an expected 1143-bp PCR product being visualized in agarose gel throughout the time in culture. Generation of MPA resistance was tested in PM-1 cells infected with the Z6 ⌬ nef gpt virus. The survival curve showing the MPA selection in PM-1 cells infected with Z6, Z6 fs nef, and Z6 ⌬ nef gpt is depicted in Fig. 4 . The mock-infected PM-1 cell had an IC50 of 0.15 g/ml, contrasting with the same cell line infected with Z6 or Z6 fsNEF that showed a lower IC50 (0.03 g/ml). The PM-1 cells infected with Z6 ⌬ nef gpt were more resistant to MPA, reaching an IC50 of 1.5 g/ml, nearly 50-fold higher than that found for cells infected with HIV not expressing the resistance gene.
Abrogation of HIV ⌬ nef gpt replication by 6-TX
At a wide range of concentrations, 6-TX is innocuous to eucaryotic cells. The E. coli gpt gene monophosphorylates 6-TX with a high specific activity. Cellular enzymes then convert 6-TX-monophosphate to 6-thioguaninemonophosphate, an effective terminator of DNA synthe-
Autoradiogram showing the immunoprecipitation of biotinlabeled protein of Z6, Z6 fsNEF, and Z6 ⌬ nef gpt extracted from PM-1-infected cells using a polyclonal antibody against a 15-mer synthetic peptide representing the N-terminal of the E. coli GPT. Lanes: 1, mock-infected; 2, PM-1 protein extract spiked with 1 g of E. coli DH5␣ cytosolic extract; 3, Z6 fsNEF 10 days postinfection; 4 to 7, Z6 ⌬ nef gpt 5, 10, 20, and 25 days postinfection, respectively. The position of migration of the molecular weight marker is depicted in the right side of the gel and a band of the predicted molecular weight, 17 kDa, is indicated by an arrow. sis. To test the ability of 6-TX to inhibit proliferation of PM-1 cells infected with Z6 ⌬ nef gpt, we cloned (by limiting dilution) a culture of PM-1 cells resistant to 2 g/ml of MPA following E. coli gpt transduction through Z6 ⌬ nef gpt infection. One clone (No. 37) was cultivated in various concentrations of 6-TX. This cell line carries one copy of Z6 ⌬ nef gpt proviral sequence per genome. For this clone, cell growth could be totally inhibited with 100 g/ml of the analog; in contrast, growth of wild-type PM-1 cells was not affected at these drug concentrations (Fig. 5 ).
Similarly, we tested the potential of 6-TX to inhibit the Z6 ⌬ nef gpt virus replication in human PBMCs. In this FIG. 3 . Growth kinetics and genetic stability in human PBMC. PBMCs were infected with Z6, Z6 fsNEF, and Z6 ⌬ nef gpt; the cells were maintained for 25 days; and HIV p24 antigen production was measured (A). Vertical bars represent the SD of the average (plotted as filled diamonds, filled squares, or filled triangles) of three p24 determinations. Genetic stability of Z6 ⌬ nef gpt was determined after four passages in hu-PBMCs. The upper x axis shows the number of viral passages corresponding to the time of infection showed on the lower x axis. PCR analysis (B) of the 3Ј-end regions of Z6 and Z6 ⌬ nef gpt was performed by isolating the proviral DNA from infected cells after each passage and using primers nef 102 and nef 103. PCR products were separated on 1.4% TBE-agarose gel. Lane 1: X174 digested with HaeIII (molecular weight markers indicated in kilobases on the right side of the figure); lanes 2 and 3: control fragments generated with pZ6 (934 bp) and pZ6 gpt (1134 bp); lanes 4 to 8: PCR products generated from the amplification of proviral DNA of Z6 ⌬ nef gpt-infected hu-PBMCs in the first, second, third, fourth, and fifth passages, respectively; and lane 9: PCR negative control.
FIG. 4.
Survival of PM-1 cells in the presence of mycophenolic acid (MPA) and the effect of infection with Z6 and Z6-recombinant viruses. The supernatant containing 10 4 TCID50 units from Z6, Z6 fsNEF, and Z6 ⌬ nef gpt was used to infect PM-1 cells in a m.o.i. of 0.1. PM-1 mock-infected cells were also used as a control in the experiment. The cells were cultivated for 10 days in RPMI media and expanded every 5 days before exposure to the selective media. The cells (10 4 ) were inoculated in a 24-well plate containing 1 ml of MPA media with different concentrations of MPA (from 0 to 10 g/ml). The cells were cultivated and the media changed every 3 days; after 15 days, the number of viable cells were counted and plotted. The percentage of survival is always related to the cell counts in the well without the drug (100% survival).
FIG. 5. 6-TX treatment can kill PM-1 cells infected with Z6 ⌬ nef gpt. Clone 37 was inoculated in 6-TX media with different concentrations of 6-thioxanthine (from 0 to 200 g/ml). The cells were cultivated and the media changed every 3 days; after 15 days, the number of viable cells were counted and plotted. PM-1 cells were used as a control in this experiment. The percentage of survival is always related to the cell counts of the well without the drug (100% survival).
case, 10 4 TCID50 of the Z6 ⌬ nef gpt virus was used to infect 5 ϫ 10 5 human PBMCs. Cells were cultivated with 100 g/ml of 6-TX. Fresh, activated human PBMCs were added to the culture every 5 days, replacing half of the culture volume, and p24 production was followed for 40 days (Fig. 6) . A considerable inhibition was seen in this experiment, and only a residual growth of the recombinant virus could be observed. The drug was removed on Day 25, and the culture was continued for another 20 days with no rebounding of the Z6 ⌬ nef gpt virus (Fig. 6) . PCR was used to detect the presence of Z6⌬ nef gpt proviral sequence in this culture. The PCR signal was not detected after 10 days postinfection, nor even after the selective pressure was withdrawn on Day 25. In contrast, the same viral culture in nonselective media was PCR positive and the signal could be easily visualized even after 40 days in culture (data not shown). The replication of Z6 fsnef and that of wild-type Z6 in human PBMCs were not affected by 6-TX, even when the cells were exposed to high doses of this compound (data not shown).
DISCUSSION
Retroviral vectors efficiently transfer gene sequences into cells and promote their stable expression. Recently, HIV has been used as a replication-competent vector for the expression of reporter genes such as chloramphenicol acetyltransferase (Terwilliger et al., 1989) and luciferase (Chen et al., 1994; Connor et al., 1995) . Other HIV recombinants have been used to study the function of viral genes (Wang and Barklis, 1993) or antiviral compounds (Nagy et al., 1994) . We constructed a replicationcompetent recombinant HIV, Z6 ⌬ nef gpt, that expresses the E. coli gpt gene under the control of the viral LTR promoter, yet lacks a competent nef gene. This virus can induce the expression of the bacterial enzyme GPT in PM-1 cells and simultaneously transduce the MPA resistance and the susceptibility to 6-TX.
The deletion of key accessory genes such as nef has been a common approach for generating attenuated HIV strains. Daniel and colleagues (1992) and others (Almond et al., 1995) found that, although deletion of SIV nef in rhesus monkeys had little or no effect on in vitro replication, infection with SIV nef (Ϫ) strains in vivo resulted in low-level viremia without development of disease. Moreover, the animals were protected against challenge with wild-type virus several years later (Almond et al., 1995) . The monkey model shows that the SIV vaccine deleted in nef has an attenuated phenotype that is stable, even though a functional nef provides a tremendous selective advantage in vivo. In adults, deletion of nef results in at least a two-log reduction in the virus load (Kestler et al., 1991) . On the other hand, deletion of vpr and other accessory genes does not appear to yield the attenuated phenotype in the monkey model (Gibbs et al., 1995) or SCID mice (Aldrovandi and Zack, 1996) . The nef gene also seems to be implicated in HIV pathogenesis in humans and a large number of viruses carrying defective or deleted nef alleles were systematically recovered from four long-term nonprogressing survivors of HIV-1 infection (Mariani et al., 1996) .
Our findings with the Z6 ⌬ nef gpt recombinant demonstrate a high genetic stability for the gpt marker in a retroviral framework, specifically using HIV Z6 as the backbone of the infectious molecular clone. A recent report has shown that an HIV-1 genome carrying the cDNA of a proteolysis-resistant NF-B inhibitor in the nef region downregulates viral expression and is highly attenuated in both Jurkat and peripheral blood mononuclear cells. This recombinant virus maintains the exogenous insert, despite 180 days of forced ex vivo passaging in tissue culture (Quinto et al., 1999) . In contrast, recombinant SIV carrying the human interferon gene in the nef coding region was highly unstable, losing the inserted DNA in 14 days during the culture without selective pressure (Giavedoni and Yilma, 1995) . In our study, the gpt marker was stable for more than 45 days in continuous passage. Perhaps the gpt gene does not interfere with the replication of HIV or increases the intracellular purine salvage pathway, thus giving the cells a selective advantage. HIV infection in lymphocytes depletes the intracellular pool of guanine (Bofil et al., 1995; Carlucci et al., 1996) . The enhancement in the purine salvage induced with the E. coli gpt expression could antagonize the viral effect in this important cellular metabolic pathway.
The introduction of the E. coli gpt gene converted HIV-1 into a 6-TX-sensitive virus through subsequent metabolization of this analog by GPT. Treatment with FIG. 6. 6-TX treatment abolishes a spreading infection in hu-PBMCs. The supernatant containing 10 4 TCID50 of Z6 ⌬ nef gpt virus was used to infect 5 ϫ 10 5 huPBMCs. The culture was cultivated with 100 g/ml of 6-TX (a drug concentration that inhibits 100% of the cell growth in PM-1 Z6 ⌬ nef gpt clone 37). Fresh, activated huPBMCs were added to the culture every 5 days, replacing half of this culture media. The 6-TX media was removed 25 days postinfection, and the culture continued with RPMI media for an additional 15 days; HIV p24 antigen production was measured (see arrow). A culture that had been similarly infected and maintained in RPMI media (without 6-TX) was used as control. The cells were maintained for 6 days and HIV p24 antigen production was measured. Vertical bars represent the SD of the average (plotted as filled squares or filled diamonds) of three p24 determinations.
6-TX can inhibit PM-1 cells harboring the Z6 ⌬ nef gpt provirus as well as the productive replication in PBMCs. Therefore, our experimental data clearly show that replication of the Z6 ⌬ nef gpt could be suppressed using a negative selective drug (6-TX).
We have demonstrated the replacement of the HIV nef gene with a functional E. coli gpt gene. Such an approach was previously found to be successful using a gpt retroviral vector to transduce the 6-TX susceptibility to murine sarcoma cells. Systemic 6-TX therapy induced durable regressions in mice previously implanted with gpt-positive K3T3 sarcoma cells. A similar approach was also used in a nude-mouse model of intracerebral tumors: grafting gpt-retrovirus-producing cells led to an 80% reduction in intracerebral tumor volumes and a 28% increase in the mean survival time of animals after 6-TX treatment (Mroz and Moolten, 1993; Ono et al., 1997) . Our findings indicate that HIV-gpt recombinants hold promise for an alternative live-attenuated HIV-1 vaccine like HIV-tk (Chakrabarti et al., 1996; Smith et al., 1996) . Further studies using animal models such as hu-PBMC-SCID mouse and HIV-2/SIV infected macaques should be done to ensure the efficacy of 6-TX treatment in abrogating the Z6 ⌬ nef gpt in vivo. Conceptually, such an approach could provide a means to formulate alternative, safer, live-attenuated HIV vaccines that carry a selectable "suicide" gene.
MATERIALS AND METHODS
Construction of Z6 ⌬ nef gpt
To replace the nef gene of Z6 infectious clone with the E. coli gpt gene, we developed a new cloning strategy, which combines PCR technology with the resistance of phosphothioate bonds to the 5Ј-3Ј double-strand-specific T7 exonuclease digestion (Kerr and Sadowski, 1972; Nikiforov et al., 1994) . Primers used to amplify the DNA target regions being manipulated presented three phosphothioate bonds at the fifteenth base from the 5Ј end. When the amplification products were digested with T7 exonuclease, the hydrolytic T7 Exo activity continued through the 5Ј end until it reached the phosphothioate bonds, generating a short, single-strand DNA tail, which contains the nucleotide integrity of the 3Ј strand. Two independently amplified products of contiguous sequences can regenerate into a stable recombinant structure when further combined in the same reaction tube in the presence of T4 DNA ligase.
The overall approach is outlined in Fig. 7 . The goal was to replace the 5Ј half of the nef gene of the Z6 clone with the entire coding sequence of the E. coli gpt gene carried by pMSG (Lee et al., 1981) . The pBR322 infectious clone of HIV-1 Z2Z6 (subtype D) (Srinivasan et al., 1987) was digested with EcoRI. A resulting 4-kb fragment contained the 3Ј end of the HIV genome, including the nef gene (Fig. 7A, Step 1) . A 6-kb fragment, encompassing the vector backbone and the HIV insert minus the 248 bp representing the 5Ј half of the nef gene, was amplified using pUC-NEF as a template (Fig. 7A, Step 2). Conditions for PCR amplifications were as described in the XL PCR kit (Perkin-Elmer, Branchburg, NJ) using 20 pmol of primers gp41RC (ATGTTAAAGCAAsAsAsGCCTTTCTA-AGCCCTGT; "s" denotes phosphothioate bonds) and nefF1 (ACTTACAAAGGAGsCsGsTTAGATCTTAGCCACT).
The cycling conditions were as follows: 16 cycles of denaturation at 94°C for 2 min and elongation at 60°C for 6 min each, followed by 25 cycles of denaturation at 94°C for 2 min and elongation at 68°C for 6 min each. Another 458-bp fragment, containing the entire E. coli gpt gene, was amplified using vector pMSG as a template. The reactions were carried out with 0.2 mM of each dNTP, 2.5 mM of MgCl 2 , 20 pmol of primers gptF2C (5Ј-TTTTGCTTTAACsAsTsGGCCGAAAAATACATCGTCA-3Ј; the GC sequence in bold in oligo gptF2 represents a mutation site included in this oligo.) and gptR2 (5Ј-TCCTTTGTAAGTTsTsAsGCGAC-CGGAGATTGGCGGGAC-3Ј), 2.5 U of Taq polymerase from Perkin-Elmer Cetus Instruments (Norwalk, CT) and 1X reaction buffer. The reactions were subjected to three cycles of 94°C for 15 s, 55°C for 1 min, and 72°C for 1 min, followed by 32 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min, and a final extension of 72°C for 5 min.
The PCR products were purified using Qiagen Qiaquick Spin PCR Purification Kit (Qiagen, Chatsworth, CA) following the standard protocol. To generate the singlestrand 3Ј end of each amplified fragment, T7 Exo enzyme was added to a final concentration of 2 U/g of PCR product. The reaction was incubated for 1 h at room temperature. Reaction tubes were placed at 70°C for 10 min to inactivate the enzyme (Fig. 7A, Step 3) . The T7 Exo-digested pUCnef and E. coli gpt gene were combined in a single tube with a 5:1 ratio of insert to vector and T4 DNA ligase was added according to the manufacturer's protocols (Rapid DNA Ligation Kit; BoehringerMannheim, Indianapolis, IN). One tenth of this ligation reaction was used to transform E. coli MAX efficiency DH5␣-competent cells (GIBCO-BRL, Gaithersburg, MD), followed by plating on ampicillin/kanamycin-containing plates (Fig. 7A, Step 4) . The plasmid DNA from the colonies was isolated and screened by PCR, using nef1 and nef2 primers (data not shown). This clone was named pUC ⌬ nef gpt. The construction was confirmed by automated DNA sequencing. The full-length clone was regenerated through partial digestion of the Z6 clone and isolation of a 9.7-kb fragment containing all sequences, except for the 4.0-kb fragment, which was donated by the pUC ⌬ nef gpt. These two fragments were ligated, transformed in E. coli MAX efficiency DH5-competent cells (GIBCO-BRL), and plated on ampicillin/kanamycin-containing plates (Fig. 7A , Steps 5 and 6). The nef gene overlapping the 3Ј LTR sequences was preserved to avoid disturbing the viral replicative function located in that piece of the genome. The 248-pb 5Ј half of the nef gene extending from the first ATG codon to the 82nd codon was deleted and replaced by a 458-bp fragment that represented the entire coding sequence of the E. coli gpt gene. The nef deletion prevented reversion of the gene and accommodated the larger gpt gene insert without greatly increasing the net size of HIV genome. The bacterial gene was manipulated by changing its original second codon AGC to GCC, to follow the Kozak translation initiation sequence, thus ensuring an efficient translation (Kozak, 1987) . In this case, the E. coli gpt gene can be expressed using the same promoter and splicing signal as the original HIV nef gene. This infectious clone was named Z6 ⌬ nef gpt (see Fig. 7B ).
A nef (Ϫ) genome control was also constructed for biological characterization of the Z6 ⌬ nef gpt virus. The HIV Z6 infectious clone was partially digested with XhoI, and the linear fragment was isolated from agarose gel. This fragment was blunt-ended by incubating it with Pfu DNA pol and a 0.2 mM dNTP mix at 72°C for 30 min. The plasmid was ligated with T4 DNA ligase and transformed in E. coli DH5␣-competent cells. Clones were selected by XhoI digestion, and those clones lacking one XhoI site (position 8890 in HIV Z6 genome) were sequenced to confirm the 4-bp insertion in the coding sequence of the nef gene, disrupting its reading frame. This infectious clone was named HIV Z6 fsnef.
Virus and cells
PM-1 was maintained in RPMI 1640 media supplemented with 10% fetal calf serum (FCS) and in selective media. Two different selective media were used: MHX (RPMI 10% FCS; MPA in variable concentrations, ranging from 0 to 10 g/ml; xanthine 200 g/ml; and hypoxanthine 25 g/ml) for positive selection and 6-TX (RPMI 10% FCS; 6-thioxanthine in variable concentrations, ranging from 0 to 100 g/ml) for negative selection. During selection, fresh media was added every 3 days to account for the half-life of their components. PBMCs were prepared from HIV-seronegative donors by Ficoll separation, washed in PBS, and stimulated in RPMI 1640 containing 10% FCS, 1% penicillin-streptomycin, L-glutamine, and supplemented with 10 units/ml interleukin-2 and 4 g/ml phytohemagglutinin-P (PHA). Cells were incubated for 48 h, and supernatant was removed and replaced with medium without PHA but with 10 units/ml of interleukin-2, during replacement experiments with positive (MPA) and negative (6-TX) selection.
HIV-Z6, HIV Z6 ⌬ nef gpt, and HIV Z6 fs nef molecular clones were generated through transfection in COS-7 cells (2 ϫ 10 5 cells in a 35-mm plate) with 1 g of purified plasmid using the lipofectamin standard protocol (Gibco-BRL, Grand Island, NY). The viruses generated in these transfections were further used to infect PM-1 cells and PBMCs. The multiplicity of infection (m.o.i.) was standardized for HIV Z6 clones and for derivatives related to p24 antigen concentration (10 4 TCID50 ϭ 1 ng of p24). The viral replication was followed with HIV p24/gag antigen determination with reagents from Coulter (Hialeah, FL). The PM-1 cell viability was determined by Trypan blue exclusion.
Expression of gpt in infected cells
PM-1 cells were infected with Z6, Z6 fsnef, and Z6 ⌬nef gpt at a m.o.i. of 0.1. At different times postinfection, 10 7 PM-1 cells were lysed with RIPA buffer (10 mM Tris-HCl, pH 7.5; 150 mM NaCl; 5 mM EDTA; 1% NaDOC; 1% Triton X-100; 1% SDS; 10 g/ml aprotinin; 2 g/ml leupeptin; 2 g/ml benzamidine; 10 g/ml TLCK; and 0.2 mM PMSF), and the total protein was biotinylated and immunoprecipitated using the cellular labeling and immunoprecipitation kit according to the protocol provided by the manufacturer (Boehringer-Manheim). The labeled protein was immunoprecipitated with a 1:500 dilution of a polyclonal rabbit antibody directed against a KLH-linked synthetic peptide (KGIIAVSRGGLVPGA) representing the GPT protein (residues 28 to 43). The final immunoprecipitated protein was analyzed in a 4-20% gradient SDS-PAGE gel (Novex, San Diego, CA). The gel was electrotransferred onto PVDF membrane using a Bio-Rad Mini trans-blot cell (Bio-Rad) under conditions described by the manufacturer. The membrane was blocked and detected by chemiluminescence (Boehringer-Mannheim).
PCR determination of proviral gpt
Total cellular DNA was extracted using the QIAamp blood kit (Qiagen). Primers nef 102 and nef 103 were used to amplify proviral DNA. This pair of primers amplifies the entire HIV-1 nef gene, producing a 934-bp amplicon with HIV Z6 and HIV Z6 fsnef and a 1134-bp amplicon with HIV Z6 ⌬ nef gpt. Taq polymerase was obtained from Perkin-Elmer Cetus and used according to the manufacturer's recommendations: 0.2 mM of each dNTP, 25 pmol of each primer, and 2.5 mM of MgCl 2 were combined in the 100-l reaction mixture. Cycling conditions were 94°C for 2 min, followed by 35 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 2 min. 
